aldosterone and Albuminuria studies

Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

Excerpt	Relevance	Reference
" Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial."	9.24	Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017)
"The aim was to compare the antiproteinuric effect of aliskiren and ramipril in hypertensive patients with type 2 diabetes and microalbuminuria."	9.17	Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2013)
" We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease."	9.17	L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013)
" In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)."	9.15	Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011)
"This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension."	9.14	Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009)
"To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)."	9.08	Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995)
"The effects of an ACE-inhibitor (ramipril), a calcium antagonist (felodipine) and placebo on glomerular filtration rate (GFR), urinary albumin/creatinine ratio, blood pressure (BP) and vasoactive hormones were investigated in a randomized, prospective, double-blind, placebo-controlled study of patients with chronic glomerulonephritis and hypertension, with measurements at entrance and after 12 and 24 months."	9.08	A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two yea ( Bech, JN; Hansen, HE; Jensen, KT; Kornerup, HJ; Nielsen, CB; Pedersen, EB; Spencer, ES; Sølling, J, 1997)
"To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)."	8.31	Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023)
" We report our long-term single-practice experience in an unusual group of five patients with chronic hyperaldosteronism (HA, including three with glucocorticoid-remediable aldosteronism, GRA) treated with low-dose amiloride (a specific epithelial sodium channel [ENaC] blocker) 5-10 (mean 7) mg daily for 14-28 (mean 20) years."	7.91	Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism. ( Hong, M; Hussain, T; Izzo, JL; Osmond, PJ, 2019)
" It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension."	7.76	Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010)
"Aldosterone breakthrough has the potential to eliminate the organ-protective effects of RA system inhibitors."	6.78	Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist. ( Fukuda, S; Sato, A, 2013)
" Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial."	5.24	Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017)
"Spironolactone reduced albuminuria along with conventional RAS inhibitors in patients with diabetic nephropathy."	5.20	Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. ( Ando, M; Araki, H; Goto, M; Imai, E; Kanasaki, K; Kato, S; Kobori, H; Koya, D; Makino, H; Maruyama, S; Matsuo, S; Nishiyama, A; Ogawa, D; Oiso, Y; Uzu, T; Wada, J, 2015)
"We aimed to assess the effect of aliskiren treatment on blood pressure, albuminuria, and kidney function in patients with chronic kidney disease (CKD)."	5.17	Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. ( Abe, M; Baba, S; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Takashima, H, 2013)
"The aim was to compare the antiproteinuric effect of aliskiren and ramipril in hypertensive patients with type 2 diabetes and microalbuminuria."	5.17	Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2013)
" We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease."	5.17	L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013)
" In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)."	5.15	Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011)
"This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension."	5.14	Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009)
"To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)."	5.08	Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995)
"The effects of an ACE-inhibitor (ramipril), a calcium antagonist (felodipine) and placebo on glomerular filtration rate (GFR), urinary albumin/creatinine ratio, blood pressure (BP) and vasoactive hormones were investigated in a randomized, prospective, double-blind, placebo-controlled study of patients with chronic glomerulonephritis and hypertension, with measurements at entrance and after 12 and 24 months."	5.08	A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two yea ( Bech, JN; Hansen, HE; Jensen, KT; Kornerup, HJ; Nielsen, CB; Pedersen, EB; Spencer, ES; Sølling, J, 1997)
"Cyclosporin A (CyA) and azathioprine (Aza) were compared with respect to renal side effects in an open controlled, randomized study of patients with rheumatoid arthritis."	5.06	Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. ( Amundsen, E; Berg, KJ; Bjerkhoel, F; Djøseland, O; Førre, O; Rugstad, HE; Westre, B, 1986)
" Spironolactone and eplerenone are the mineralocorticoid receptor (MR) antagonists currently available for the treatment of hypertension."	4.82	Mineralocorticoid receptor antagonists and hypertension: is there a rationale? ( Gumieniak, O; Williams, GH, 2004)
" In our study, we studied if continuous treatment with a mineralocorticoid receptor antagonist, spironolactone (30 mg/kg/day) for 20 days can: 1) attenuate hypertension development and restore inverted 24-h BP rhythm in hypertensive transgenic (mRen-2)27 rats (TGR) measured by telemetry; 2) improve function of the kidneys and heart; 3) be protective against high salt load (1% in water) by mitigating oxidative injury and improving kidney function."	4.31	Mineralocorticoid receptor blockade protects the kidneys but does not affect inverted blood pressure rhythm in hypertensive transgenic (mRen-2)27 rats. ( Kopkan, L; Majzunova, M; Molcan, L; Sutovska, H; Sykora, M; Zeman, M, 2023)
"To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)."	4.31	Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023)
" We report our long-term single-practice experience in an unusual group of five patients with chronic hyperaldosteronism (HA, including three with glucocorticoid-remediable aldosteronism, GRA) treated with low-dose amiloride (a specific epithelial sodium channel [ENaC] blocker) 5-10 (mean 7) mg daily for 14-28 (mean 20) years."	3.91	Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism. ( Hong, M; Hussain, T; Izzo, JL; Osmond, PJ, 2019)
" It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension."	3.76	Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010)
"Urinary excretion of albumin and beta 2-microglobulin were measured in 13 patients with congestive heart failure, NYHA class II-IV, before and after captopril treatment for 4 weeks, and in 13 healthy control subjects."	3.68	Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. ( Bagger, JP; Eiskjaer, H; Mogensen, CE; Pedersen, EB; Schmitz, A, 1992)
"Aldosterone breakthrough has the potential to eliminate the organ-protective effects of RA system inhibitors."	2.78	Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist. ( Fukuda, S; Sato, A, 2013)
" Adverse events related to BAY 94-8862 were infrequent and mostly mild."	2.78	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. ( Filippatos, G; Gheorghiade, M; Kim, SY; Kober, L; Kolkhof, P; Krum, H; Nowack, C; Pitt, B; Ponikowski, P; Zannad, F, 2013)
"Aldosterone breakthrough was seen to be equal in hypertensive patients with diabetes mellitus treated with candesartan or valsartan."	2.73	Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007)
"Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg."	2.71	Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. ( Boomsma, F; Jensen, BR; Parving, HH; Rossing, K; Schjoedt, KJ, 2005)
"It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape)."	2.71	Effectiveness of aldosterone blockade in patients with diabetic nephropathy. ( Hayashi, K; Naruse, M; Saruta, T; Sato, A, 2003)
"Early stage of diabetic nephropathy does not influence the examined hormones level."	2.68	[Activity of the renin-angiotensin-aldosterone system in euglycemic type I diabetic patients on intensive insulin treatment without diabetic neuropathy]. ( Górska, J; Grzeszczak, W; Krywult, D; Lacka, B; Morawin, E; Strojek, K, 1995)
"It showed that cardiac hypertrophy was associated with obesity while microalbuminuria was related to plasma aldosterone concentration (PAC) in PA patients."	1.72	Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome. ( Bu, X; He, H; Li, Y; Liu, X; Sun, F; Yan, Z; Zhang, H; Zhao, Z; Zhu, Z, 2022)
"Youth with type 2 diabetes (T2D) have high rates of obesity, hypertension and suboptimal glycemic control."	1.56	An evaluation of renin-angiotensin system markers in youth with type 2 diabetes and associations with renal outcomes. ( Blydt-Hansen, T; Burns, K; Dart, AB; Dyck, J; Hamilton, J; Mahmud, F; Scholey, J; Sellers, EA; Sochett, E; Wicklow, B, 2020)
"Primary aldosteronism is characterized by inappropriate overproduction of aldosterone by adrenal lesions and leads to hypertension."	1.51	Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism. ( Ichihara, A; Morimoto, S; Seki, Y; Watanabe, D; Yamashita, K, 2019)
"Microalbuminuria was determined from 24-hour urine collections."	1.48	Aldosterone as a mediator of microvascular and macrovascular damage in a population of normotensive to early-stage hypertensive individuals. ( Anyfanti, P; Douma, S; Gavriilaki, E; Gkaliagkousi, E; Lazaridis, A; Nikolaidou, B; Triantafyllou, A; Vamvakis, A, 2018)
"Symmetric dimethylarginine (SDMA) was measured by immunoassay."	1.46	The Renin-Angiotensin-Aldosterone System in Greyhounds and Non-Greyhound Dogs. ( Couto, CG; Hoepf, TM; Iazbik, MC; Kellogg, C; Martinez, J; Pressler, BM; Radin, MJ, 2017)
"Aldosterone (Aldo) has been shown as an important contributor of podocyte injury."	1.46	NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. ( Bai, M; Chen, Y; He, JC; Huang, S; Jia, Z; Zhang, A; Zhang, Y; Zhao, M, 2017)
"Canrenone is a derivative of spironolactone with lower antiandrogen activity."	1.40	Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. ( Armanini, D; Bordin, L; Clari, G; Donà, G; Sabbadin, C, 2014)
"Primary aldosteronism (PA) is the most common cause of endocrine hypertension with a high frequency of cardiovascular complications."	1.38	Have main types of primary aldosteronism different phenotype? ( Holaj, R; Indra, T; Petrák, O; Rosa, J; Somlóová, Z; Strauch, B; Widimský, J; Zelinka, T, 2012)
"Obesity is a major risk factor for hypertension."	1.38	Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity. ( Ali, MI; Belin de Chantemèle, EJ; Fulton, DJ; Mintz, JD; Rainey, WE; Stepp, DW; Tremblay, ML, 2012)
"It was hypothesized that preeclampsia is associated with plasmin-dependent ability of tubular fluid to activate ENaC."	1.38	Urinary plasmin activates collecting duct ENaC current in preeclampsia. ( Bistrup, C; Buhl, KB; Frederiksen-Møller, B; Friis, UG; Gulaveerasingam, A; Jensen, BL; Jespersen, B; Ovesen, P; Svenningsen, P, 2012)
" RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm."	1.35	A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. ( Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008)
"Aldosterone is an important mediator of cardiovascular and renal remodeling."	1.35	Increased aldosterone levels in a model of type 2 diabetes mellitus. ( Birner, C; Endemann, DH; Fredersdorf, S; Heitzmann, D; Luchner, A; Muders, F; Resch, M; Riegger, GA; Schmid, P; Stoelcker, B; Ulucan, C; Weil, J, 2009)
"Spironolactone treatment did not induce any significant change in blood glucose levels and blood pressure."	1.33	Role of aldosterone in diabetic nephropathy. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS, 2005)
"We recruited 80 patients with Type 1 diabetes of more than 10 years' duration and 75 age-matched controls."	1.31	The renin-angiotensin-aldosterone system is suppressed in adults with Type 1 diabetes. ( Arnqvist, HJ; Bojestig, M; Karlberg, BE; Ludvigsson, J; Nystrom, FH, 2000)
"RFR was examined in 33 IDDM patients in similar glycaemic and metabolic control and compared to 12 healthy control subjects, during eight 1 h clearance periods prior to, during and after a 3-h stimulation by amino acid infusion (4."	1.30	Renal functional reserve in IDDM patients. ( Ader, JL; Hanaire-Broutin, H; Sackmann, H; Tack, I; Tauber, JP; Tran-Van, T, 1998)
"In both IDDM groups, the overnight excretion of tetrahydrocortisol (THF), allo-tetrahydrocortisol (allo-THF), and tetrahydrocortisone (THE) was lower than that in the control group (P < 0."	1.29	Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition. ( Dullaart, RP; Hoogenberg, K; Muntinga, JH; Pratt, JJ; Sluiter, WJ; Smit, AJ; Ubels, FL; Wolthers, BG, 1995)
"Aldosterone and AVP were lower in non-dippers (p < 0."	1.29	Night blood pressure: relation to organ lesions in microalbuminuric type 1 diabetic patients. ( Christensen, PD; Christiansen, JS; Hansen, KW; Mogensen, CE; Pedersen, EB; Sørensen, K, 1995)
"As our model we selected type 1 diabetes with peripheral circulatory hyperinsulinemia induced by sc insulin treatment."	1.29	Nocturnal blood pressure elevation is related to adrenomedullary hyperactivity, but not to hyperinsulinemia, in nonobese normoalbuminuric type 1 diabetes. ( Gromeier, S; Kerner, W; Kohlmann, T; Look, D; Peters, A, 1996)
"These findings indicate that primary aldosteronism is associated with excessive urinary albumin excretion."	1.29	Albuminuria in untreated patients with primary aldosteronism or essential hypertension. ( Halimi, JM; Mimran, A, 1995)
"PRA at time zero (Hf-IDDM = 2."	1.29	Renin-aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration. ( de Azevedo, MJ; Gross, JL; Ramos, OL, 1995)
"A new case of Bartter's syndrome is described."	1.25	[Bartter's disease associated with hypercorticism, phosphate and magnesium deficiencies and familial renal tubular disease]. ( François, R; Longin, B; Moreau, P; Sann, L; Sassard, J, 1975)

Research

Studies (110)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Doubling of Interstitium or Any ESRD

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (4.55)	18.7374
1990's	19 (17.27)	18.2507
2000's	31 (28.18)	29.6817
2010's	47 (42.73)	24.3611
2020's	8 (7.27)	2.80

Authors	Studies
Bu, X	1
Sun, F	1
Zhang, H	1
Liu, X	1
Zhao, Z	1
He, H	1
Li, Y	2
Yan, Z	1
Zhu, Z	1
Fujii, W	1
Shibata, S	1
Sutovska, H	1
Molcan, L	1
Majzunova, M	1
Sykora, M	1
Kopkan, L	1
Zeman, M	1
Dattani, R	1
Ul-Haq, Z	1
Shah, M	1
Goldet, G	1
Darzi, LA	1
Ashrafian, H	1
Kamalati, T	1
Frankel, AH	1
Tam, FWK	1
Li, J	1
Yang, N	1
Chou, H	1
Shi, L	1
Wei, M	1
Yamashita, K	1
Morimoto, S	1
Seki, Y	1
Watanabe, D	1
Ichihara, A	2
Dart, AB	1
Wicklow, B	1
Scholey, J	1
Sellers, EA	1
Dyck, J	1
Mahmud, F	1
Sochett, E	1
Hamilton, J	1
Blydt-Hansen, T	1
Burns, K	1
Mabuza, LP	1
Gamede, MW	1
Maikoo, S	1
Booysen, IN	1
Ngubane, PS	1
Khathi, A	1
Nakamura, Y	1
Kobayashi, H	1
Tanaka, S	1
Hatanaka, Y	1
Fukuda, N	1
Abe, M	6
Antlanger, M	1
Bernhofer, S	1
Kovarik, JJ	1
Kopecky, C	1
Kaltenecker, CC	1
Domenig, O	1
Poglitsch, M	1
Säemann, MD	1
Kato, Y	1
Mori, K	1
Kasahara, M	1
Osaki, K	1
Ishii, A	1
Mori, KP	1
Toda, N	1
Ohno, S	1
Kuwabara, T	1
Tokudome, T	1
Kishimoto, I	1
Saleem, MA	1
Matsusaka, T	1
Nakao, K	1
Mukoyama, M	1
Yanagita, M	1
Yokoi, H	1
Martinez, J	1
Kellogg, C	1
Iazbik, MC	1
Couto, CG	1
Pressler, BM	1
Hoepf, TM	1
Radin, MJ	1
Fujihara, CK	2
Kowala, MC	2
Breyer, MD	1
Sena, CR	1
Rodrigues, MV	1
Arias, SCA	1
Fanelli, C	2
Malheiros, DM	2
Jadhav, PK	1
Montrose-Rafizadeh, C	1
Krieger, JE	1
Zatz, R	2
Catena, C	1
Colussi, G	1
Martinis, F	1
Novello, M	1
Sechi, LA	1
Gkaliagkousi, E	1
Anyfanti, P	1
Triantafyllou, A	1
Gavriilaki, E	1
Nikolaidou, B	1
Lazaridis, A	1
Vamvakis, A	1
Douma, S	1
Nishihara, M	1
Takesue, K	1
Hirooka, Y	1
Butler, MJ	1
Ramnath, R	1
Kadoya, H	1
Desposito, D	1
Riquier-Brison, A	1
Ferguson, JK	1
Onions, KL	1
Ogier, AS	1
ElHegni, H	1
Coward, RJ	1
Welsh, GI	1
Foster, RR	1
Peti-Peterdi, J	1
Satchell, SC	1
Huang, Y	1
Ting, PY	1
Yao, TM	1
Homma, T	1
Brooks, D	1
Katayama Rangel, I	1
Adler, GK	1
Romero, JR	1
Williams, JS	1
Pojoga, LH	1
Williams, GH	3
Lytvyn, Y	1
Godoy, LC	1
Scholtes, RA	1
van Raalte, DH	1
Cherney, DZ	1
Dong, D	1
Fan, TT	1
Ji, YS	1
Yu, JY	1
Wu, S	1
Zhang, L	1
Izzo, JL	1
Hong, M	1
Hussain, T	1
Osmond, PJ	1
Fogari, R	1
Mugellini, A	1
Zoppi, A	1
Preti, P	1
Maffioli, P	1
Perrone, T	1
Derosa, G	1
Arias, SC	1
Valente, CP	1
Machado, FG	1
Origassa, CS	1
de Brito, T	1
Camara, NO	1
Pitt, B	1
Kober, L	1
Ponikowski, P	1
Gheorghiade, M	1
Filippatos, G	1
Krum, H	1
Nowack, C	1
Kolkhof, P	1
Kim, SY	1
Zannad, F	1
Sato, A	3
Fukuda, S	2
Issa, N	1
Ortiz, F	1
Reule, SA	1
Kukla, A	1
Kasiske, BL	1
Mauer, M	1
Jackson, S	1
Matas, AJ	1
Ibrahim, HN	1
Najafian, B	1
Armanini, D	1
Sabbadin, C	1
Donà, G	1
Clari, G	1
Bordin, L	1
Kawada, N	1
Isaka, Y	1
Kitamura, H	1
Rakugi, H	1
Moriyama, T	1
Ameri, P	1
Canepa, M	1
Fabbi, P	1
Leoncini, G	1
Milaneschi, Y	1
Mussap, M	1
AlGhatrif, M	1
Balbi, M	1
Viazzi, F	1
Murialdo, G	1
Pontremoli, R	1
Brunelli, C	1
Ferrucci, L	1
Tani, S	1
Takahashi, A	1
Nagao, K	1
Hirayama, A	1
Torres, VE	1
Abebe, KZ	1
Chapman, AB	1
Schrier, RW	1
Braun, WE	1
Steinman, TI	1
Winklhofer, FT	1
Brosnahan, G	1
Czarnecki, PG	1
Hogan, MC	1
Miskulin, DC	1
Rahbari-Oskoui, FF	1
Grantham, JJ	1
Harris, PC	1
Flessner, MF	1
Moore, CG	1
Perrone, RD	1
Kancir, ASP	1
Johansen, JK	1
Ekeloef, NP	1
Pedersen, EB	5
Kato, S	1
Maruyama, S	1
Makino, H	1
Wada, J	1
Ogawa, D	1
Uzu, T	1
Araki, H	1
Koya, D	1
Kanasaki, K	1
Oiso, Y	1
Goto, M	1
Nishiyama, A	2
Kobori, H	1
Imai, E	1
Ando, M	1
Matsuo, S	1
Devarajan, S	1
Yahiro, E	1
Uehara, Y	1
Habe, S	1
Miura, S	1
Saku, K	1
Urata, H	1
Weir, MR	1
Bakris, GL	1
Gross, C	1
Mayo, MR	1
Garza, D	1
Stasiv, Y	1
Yuan, J	1
Berman, L	1
Hahn, RG	1
Grankvist, N	1
Krizhanovskii, C	1
Bai, M	1
Chen, Y	1
Zhao, M	1
Zhang, Y	1
He, JC	1
Huang, S	1
Jia, Z	2
Zhang, A	2
Oxlund, C	1
Kurt, B	1
Schwarzensteiner, I	1
Hansen, MR	1
Stæhr, M	1
Svenningsen, P	2
Jacobsen, IA	1
Hansen, PB	1
Thuesen, AD	1
Toft, A	1
Hinrichs, GR	1
Bistrup, C	2
Jensen, BL	2
Major, TC	1
Olszewski, B	1
Rosebury, W	1
Okerberg, C	1
Carlson, T	1
Ostroski, R	1
Schroeder, R	1
Leadley, R	1
Fredersdorf, S	1
Endemann, DH	1
Luchner, A	1
Heitzmann, D	1
Ulucan, C	1
Birner, C	1
Schmid, P	1
Stoelcker, B	1
Resch, M	1
Muders, F	1
Riegger, GA	1
Weil, J	1
Fujita, T	2
Jansen, PM	1
Danser, AH	1
Imholz, BP	1
van den Meiracker, AH	1
Park, JK	1
Theuer, S	1
Kirsch, T	1
Lindschau, C	1
Klinge, U	1
Heuser, A	1
Plehm, R	1
Todiras, M	1
Carmeliet, P	1
Haller, H	1
Luft, FC	1
Muller, DN	1
Fiebeler, A	1
Nakamura, T	1
Kataoka, K	1
Fukuda, M	1
Nako, H	1
Tokutomi, Y	1
Dong, YF	1
Ichijo, H	1
Ogawa, H	1
Kim-Mitsuyama, S	1
Kinouchi, K	1
Sakoda, M	1
Kurauchi-Mito, A	1
Itoh, H	1
Pichler, RH	1
de Boer, IH	1
Konoshita, T	1
Makino, Y	1
Kimura, T	1
Fujii, M	1
Wakahara, S	1
Arakawa, K	1
Inoki, I	1
Nakamura, H	1
Miyamori, I	1
Liang, W	1
Chen, C	1
Shi, J	1
Ren, Z	1
Hu, F	1
van Goor, H	1
Singhal, PC	1
Ding, G	1
Velagaleti, RS	1
Gona, P	2
Larson, MG	3
Wang, TJ	2
Levy, D	3
Benjamin, EJ	3
Selhub, J	2
Jacques, PF	2
Meigs, JB	3
Tofler, GH	1
Vasan, RS	3
Fox, CS	2
Tofler, G	1
Hwang, SJ	2
Okada, K	5
Maruyama, N	5
Matsumoto, S	2
Maruyama, T	1
Matsumoto, K	2
Soma, M	5
Wang, N	1
Tidwell, TJ	1
Yang, T	1
Irita, J	1
Okura, T	1
Jotoku, M	1
Nagao, T	1
Enomoto, D	1
Kurata, M	1
Desilva, VR	1
Miyoshi, K	1
Matsui, Y	1
Uede, T	1
Denhardt, DT	1
Rittiling, SR	1
Higaki, J	1
Suzuki, H	3
Fujii, Y	1
Ito, M	1
Yoshida, Y	2
Inoshita, A	2
Baba, S	1
Takashima, H	1
Somlóová, Z	1
Indra, T	1
Rosa, J	1
Petrák, O	1
Strauch, B	1
Zelinka, T	1
Holaj, R	1
Widimský, J	1
Buhl, KB	1
Friis, UG	1
Gulaveerasingam, A	1
Ovesen, P	1
Frederiksen-Møller, B	1
Jespersen, B	2
Belin de Chantemèle, EJ	1
Ali, MI	1
Mintz, JD	1
Rainey, WE	1
Tremblay, ML	1
Fulton, DJ	1
Stepp, DW	1
Andersen, RF	1
Nørgaard, H	1
Hagstrøm, S	1
Bjerre, J	1
Rittig, S	1
Hayashi, K	1
Naruse, M	1
Saruta, T	1
POLIANTSEVA, LR	1
ERMOLENKO, VM	1
Vedovato, M	1
Lepore, G	1
Coracina, A	1
Dodesini, AR	1
Jori, E	1
Tiengo, A	1
Del Prato, S	1
Trevisan, R	1
Mogensen, CE	3
Cooper, ME	2
Gumieniak, O	1
Schjoedt, KJ	2
Andersen, S	1
Rossing, P	1
Tarnow, L	1
Parving, HH	2
Halimi, JM	2
Rossing, K	1
Jensen, BR	1
Boomsma, F	1
Horackova, M	1
Schück, O	1
Komers, R	1
Charvat, J	1
Teplan, V	1
Kvapil, M	1
Cha, DR	1
Kang, YS	1
Han, SY	1
Jee, YH	1
Han, KH	1
Kim, HK	1
Han, JY	1
Kim, YS	1
Weekers, L	1
Bouhanick, B	1
Hadjadj, S	1
Gallois, Y	1
Roussel, R	1
Pean, F	1
Ankotche, A	1
Chatellier, G	1
Alhenc-Gelas, F	1
Lefebvre, PJ	1
Marre, M	1
van de Wal, RM	1
Asselbergs, FW	1
Plokker, HW	1
Smilde, TD	1
Lok, D	1
van Veldhuisen, DJ	1
van Gilst, WH	1
Voors, AA	1
Ma, J	1
Weisberg, A	1
Griffin, JP	1
Vaughan, DE	1
Fogo, AB	1
Brown, NJ	1
Leip, EP	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Multi-center Study to Assess Safety and Tolerability of Different Oral Doses of BAY94-8862 in Subjects With Stable Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Mild (Part A) or Moderate (Part B) Chronic [NCT01345656]	Phase 2	457 participants (Actual)	Interventional	2011-05-09	Completed
Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients[NCT00067990]	Phase 4	153 participants (Actual)	Interventional	2002-12-31	Completed
HALT Progression of Polycystic Kidney Disease Study B[NCT01885559]	Phase 3	486 participants (Actual)	Interventional	2006-01-31	Completed
Effect of Hydroxyethyl Starch on Renal Handling of Sodium and Water, Vasoactive Hormones,Biomarkers and the Circulatory System in Patients Undergoing Radical Prostatectomy[NCT01486563]	Phase 4	40 participants (Actual)	Interventional	2012-01-31	Completed
Increased Activity of the Epithelial Sodium Channel (ENaC) in Diabetic Nephropathy[NCT01918488]		80 participants (Anticipated)	Interventional	2013-10-31	Enrolling by invitation
EDUCATION TO DECREASE IN SODIUM INTAKE IN UNIVERSITY STUDENTS EVALUATED WITH 24 HOUR URINARY SODIUM EXCRETION: RANDOMIZED CONTROLLED TRIAL[NCT04894344]		114 participants (Anticipated)	Interventional	2020-10-28	Recruiting
Association of BsmI Polymorphisms in Vitamin D Receptor Gene With Diabetic Kidney Disease[NCT03621384]		93 participants (Actual)	Observational	2014-11-30	Completed
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria[NCT00320879]	Phase 4	52 participants	Interventional	2003-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Doubling of the interstitial or any defined ESRD (including IF/TA) (NCT00067990)
Timeframe: Baseline to 5 years

Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD

Intervention	Participants (Count of Participants)
Losartan	6
Placebo	12

Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA) (NCT00067990)
Timeframe: Baseline and 5 Years Post Transplant

Albuminuria

Intervention	Participants (Count of Participants)
Losartan	7
Placebo	15

Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Aldosterone

Intervention	annual percent change (Mean)
ACE-I + Placebo	7.5
ACE-I + ARB	7.3

Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up at 8 years (annually assessed)

Back or Flank Pain

Intervention	annual percent change (Mean)
ACE-I + Placebo	-8.8
ACE-I + ARB	-10.2

Report of back or flank pain since the last visit (yes or no) (NCT01885559)
Timeframe: 48 months

Cardiovascular Hospitalizations

Intervention	percentage of participants at 48 months (Number)
ACE-I + Placebo	43
ACE-I + ARB	46

Cause-specific hospitalizations (cardiovascular) (NCT01885559)
Timeframe: up to 8 years

Hospitalizations

Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.

Intervention	events (Number)
ACE-I + Placebo	29
ACE-I + ARB	16

Intervention	events (Number)
ACE-I + Placebo	173
ACE-I + ARB	136

(NCT01885559)
Timeframe: Patients followed for 5-8 years with average of 6.5 years follow up

Quality of Life Mental Component Summary

Intervention	participants (Number)
ACE-I + Placebo	116
ACE-I + ARB	115

Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Quality of Life Physical Component Summary

Intervention	units on a scale per year (Mean)
ACE-I + Placebo	-0.031
ACE-I + ARB	-0.079

Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Article	Year
Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges. International journal of molecular sciences, 2023, Apr-23, Volume: 24, Issue:9 Topics: Albuminuria; Aldosterone; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Receptors, Mineral	2023
Mineralocorticoid Antagonism and Diabetic Kidney Disease. Current diabetes reports, 2019, 01-23, Volume: 19, Issue:1 Topics: Adult; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases;	2019
Aldosterone and CKD in metabolic syndrome. Current hypertension reports, 2008, Volume: 10, Issue:6 Topics: Albuminuria; Aldosterone; Biomarkers; Female; Humans; Kidney Failure, Chronic; Male; Metabolic Syndr	2008
Aldosterone-receptor antagonism in hypertension. Journal of hypertension, 2009, Volume: 27, Issue:4 Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; D	2009
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease. Current diabetes reports, 2010, Volume: 10, Issue:4 Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Benzimidazoles; Be	2010
Diabetic renal disease: from recent studies to improved clinical practice. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:1 Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood G	2004
Mineralocorticoid receptor antagonists and hypertension: is there a rationale? Current hypertension reports, 2004, Volume: 6, Issue:4 Topics: Albuminuria; Aldosterone; Animals; Drug Therapy, Combination; Eplerenone; Humans; Hyperkalemia; Hype	2004
Secondary rise of albuminuria under AT1-receptor blockade--what is the potential role of aldosterone escape? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:1 Topics: Albuminuria; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Humans;	2007
Some aspects of kidney function, the renin-aldosterone system and sympathetic activity in essential hypertension. Acta medica Scandinavica. Supplementum, 1980, Volume: 636 Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; Aldosterone; Catecholamines; Female; Glomerular Fil	1980

Article	Year
Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Annals of medicine, 2017, Volume: 49, Issue:6 Topics: Adult; Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Female	2017
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:4 Topics: Adult; Aged; Albumins; Albuminuria; Aldosterone; Amides; Antihypertensive Agents; Arterial Pressure;	2013
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European heart journal, 2013, Volume: 34, Issue:31 Topics: Administration, Oral; Aged; Albuminuria; Aldosterone; Blood Pressure; Cardio-Renal Syndrome; Creatin	2013
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist. Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:10 Topics: Aged; Albuminuria; Aldosterone; Amides; Blood Pressure; Dose-Response Relationship, Drug; Drug Thera	2013
The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. Kidney international, 2014, Volume: 85, Issue:2 Topics: Adult; Albuminuria; Aldosterone; Allografts; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Bi	2014
A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:2 Topics: Adult; Aged; Albuminuria; Aldosterone; Blood Pressure; Diastole; Eplerenone; Female; Glomerular Filt	2015
Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine. International heart journal, 2014, Volume: 55, Issue:6 Topics: Aged; Albuminuria; Aldosterone; Blood Pressure; Calcium Channel Blockers; Creatinine; Dihydropyridin	2014
Angiotensin blockade in late autosomal dominant polycystic kidney disease. The New England journal of medicine, 2014, Dec-11, Volume: 371, Issue:24 Topics: Adolescent; Adult; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co	2014
The effect of 6% hydroxyethyl starch 130/0.4 on renal function, arterial blood pressure, and vasoactive hormones during radical prostatectomy: a randomized controlled trial. Anesthesia and analgesia, 2015, Volume: 120, Issue:3 Topics: Acute-Phase Proteins; Aged; Albuminuria; Aldosterone; Angiotensin II; Arterial Pressure; Biomarkers;	2015
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical and experimental nephrology, 2015, Volume: 19, Issue:6 Topics: Adult; Aged; Albuminuria; Aldosterone; Asian People; Blood Pressure; Diabetes Mellitus, Type 2; Diab	2015
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney international, 2016, Volume: 90, Issue:3 Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy	2016
Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. Pflugers Archiv : European journal of physiology, 2017, Volume: 469, Issue:5-6 Topics: Adult; Aged; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Diabetic Nephropathies; Fem	2017
Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertension research : official journal of the Japanese Society of Hypertension, 2009, Volume: 32, Issue:12 Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Asian People; Blood Pressure; Cross-Over S	2009
A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. Journal of hypertension, 2010, Volume: 28, Issue:10 Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin I; Angiotensin II; Blood Pressure; Calcium C	2010
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:2 Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu	2011
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:8 Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; B	2011
Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. Hypertension research : official journal of the Japanese Society of Hypertension, 2012, Volume: 35, Issue:8 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Albuminuria; Aldosterone; Amides; Amlodipine; Angiotensin	2012
Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Heart and vessels, 2013, Volume: 28, Issue:4 Topics: Aged; Albuminuria; Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabeti	2013
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart and vessels, 2013, Volume: 28, Issue:4 Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv	2013
Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:1 Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diab	2003
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia, 2004, Volume: 47, Issue:2 Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die	2004
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia, 2004, Volume: 47, Issue:2 Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die	2004
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia, 2004, Volume: 47, Issue:2 Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die	2004
Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia, 2004, Volume: 47, Issue:2 Topics: Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Die	2004
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia, 2004, Volume: 47, Issue:11 Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Melli	2004
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney international, 2005, Volume: 68, Issue:3 Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood P	2005
Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment. International journal of clinical pharmacology and therapeutics, 2005, Volume: 43, Issue:9 Topics: Aged; Aged, 80 and over; Albuminuria; Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Creatini	2005
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. American journal of hypertension, 2007, Volume: 20, Issue:12 Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co	2007
Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. Diabetes care, 1995, Volume: 18, Issue:7 Topics: Albuminuria; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Blood P	1995
Randomly allocated study of the effects of standard therapy versus ACE inhibition on micro-albuminuria in essential hypertension. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1994, Volume: 12, Issue:4 Topics: Adrenergic beta-Antagonists; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blo	1994
Amlodipine in ambulatory hypertensive patients: humoral and haemodynamic effects. International journal of clinical pharmacology research, 1993, Volume: 13, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Amlodipine; Blood Pressure; Cholesterol; F	1993
[Activity of the renin-angiotensin-aldosterone system in euglycemic type I diabetic patients on intensive insulin treatment without diabetic neuropathy]. Polskie Archiwum Medycyny Wewnetrznej, 1995, Volume: 94, Issue:3 Topics: Adult; Albuminuria; Aldosterone; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Insulin;	1995
A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two yea Scandinavian journal of clinical and laboratory investigation, 1997, Volume: 57, Issue:8 Topics: Adolescent; Adult; Aged; Albuminuria; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inh	1997
A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes care, 2002, Volume: 25, Issue:4 Topics: Albuminuria; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cr	2002
Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney international, 1986, Volume: 29, Issue:6 Topics: Albuminuria; Aldosterone; Arthritis, Rheumatoid; Azathioprine; beta 2-Microglobulin; Blood Pressure;	1986

Article	Year
Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome. Journal of diabetes research, 2022, Volume: 2022 Topics: Albuminuria; Aldosterone; Cardiomegaly; Carotid Intima-Media Thickness; Glucose; Humans; Hyperaldost	2022
Mineralocorticoid receptor blockade protects the kidneys but does not affect inverted blood pressure rhythm in hypertensive transgenic (mRen-2)27 rats. Molecular and cellular endocrinology, 2023, 07-15, Volume: 572 Topics: Albuminuria; Aldosterone; Animals; Animals, Genetically Modified; Blood Pressure; Hypertension; Kidn	2023
Association and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study. PloS one, 2023, Volume: 18, Issue:8 Topics: Albuminuria; Aldosterone; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypertension; London; Mi	2023
Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. BMC cardiovascular disorders, 2023, 10-17, Volume: 23, Issue:1 Topics: Albuminuria; Aldosterone; Blood Pressure; Case-Control Studies; Essential Hypertension; Humans; Hype	2023
Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism. Hypertension research : official journal of the Japanese Society of Hypertension, 2019, Volume: 42, Issue:12 Topics: Adult; Aged; Albuminuria; Aldosterone; Ankle Brachial Index; Biomarkers; Blood Pressure; C-Reactive	2019
An evaluation of renin-angiotensin system markers in youth with type 2 diabetes and associations with renal outcomes. Pediatric diabetes, 2020, Volume: 21, Issue:7 Topics: Adolescent; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensinogen; Biomarkers;	2020
Amelioration of risk factors associated with diabetic nephropathy in diet-induced pre-diabetic rats by an uracil-derived diimine ruthenium(II) compound. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 129 Topics: Albuminuria; Aldosterone; Animals; Biomarkers; Cell Adhesion Molecules; Creatinine; Diabetic Nephrop	2020
Association between plasma aldosterone and markers of tubular and glomerular damage in primary aldosteronism. Clinical endocrinology, 2021, Volume: 94, Issue:6 Topics: Albuminuria; Aldosterone; Biomarkers; Cross-Sectional Studies; Humans; Hyperaldosteronism; Retrospec	2021
Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. Scientific reports, 2017, 04-21, Volume: 7 Topics: Albuminuria; Aldosterone; Animals; Apoptosis; Mice; Mice, Knockout; Natriuretic Peptides; p38 Mitoge	2017
The Renin-Angiotensin-Aldosterone System in Greyhounds and Non-Greyhound Dogs. Journal of veterinary internal medicine, 2017, Volume: 31, Issue:4 Topics: Albuminuria; Aldosterone; Animals; Arginine; Creatinine; Dogs; Female; Hemodynamics; Male; Peptidyl-	2017
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy. Scientific reports, 2017, 08-11, Volume: 7, Issue:1 Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Losartan; Mineralocorticoid Receptor	2017
Microalbuminuria and plasma aldosterone levels in nondiabetic treatment-naïve patients with hypertension. Journal of hypertension, 2017, Volume: 35, Issue:12 Topics: Adult; Aged; Albuminuria; Aldosterone; Female; Humans; Hypertension; Hypertension, Renal; Kidney; Ki	2017
Aldosterone as a mediator of microvascular and macrovascular damage in a population of normotensive to early-stage hypertensive individuals. Journal of the American Society of Hypertension : JASH, 2018, Volume: 12, Issue:1 Topics: Adult; Albuminuria; Aldosterone; Blood Pressure; Correlation of Data; Female; Humans; Hypertension;	2018
Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease. Clinical and experimental hypertension (New York, N.Y. : 1993), 2019, Volume: 41, Issue:3 Topics: Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Combined Mo	2019
Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx. Kidney international, 2019, Volume: 95, Issue:1 Topics: Albuminuria; Aldosterone; Animals; Cell Line; Disease Models, Animal; Endothelial Cells; Glycocalyx;	2019
Histone demethylase LSD1 deficiency and biological sex: impact on blood pressure and aldosterone production. The Journal of endocrinology, 2019, 02-01, Volume: 240, Issue:2 Topics: Age Factors; Albuminuria; Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Female; His	2019
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. International urology and nephrology, 2019, Volume: 51, Issue:4 Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Autophagy; Beclin-1; Diabetes Me	2019
Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism. Journal of clinical hypertension (Greenwich, Conn.), 2019, Volume: 21, Issue:8 Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Albuminuria; Aldosterone; Amiloride; Ankle Brachial Index;	2019
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy. PloS one, 2013, Volume: 8, Issue:2 Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi	2013
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:7 Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenone; Humans; Hypertension;	2014
Vitamin D modulates the association of circulating insulin-like growth factor-1 with carotid artery intima-media thickness. Atherosclerosis, 2014, Volume: 236, Issue:2 Topics: Aged; Aged, 80 and over; Aging; Albuminuria; Aldosterone; Apoptosis; Baltimore; Body Mass Index; Car	2014
Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension. American journal of physiology. Heart and circulatory physiology, 2015, Dec-01, Volume: 309, Issue:11 Topics: Albuminuria; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve	2015
Urinary Analysis of Fluid Retention in the General Population: A Cross-Sectional Study. PloS one, 2016, Volume: 11, Issue:10 Topics: Adult; Albuminuria; Aldosterone; Body Fluids; Creatinine; Cross-Sectional Studies; Dehydration; Fema	2016
NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. American journal of physiology. Renal physiology, 2017, 04-01, Volume: 312, Issue:4 Topics: Albuminuria; Aldosterone; Animals; Apoptosis; Caspase 1; Cell Line; Dose-Response Relationship, Drug	2017
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. Cardiovascular drugs and therapy, 2008, Volume: 22, Issue:6 Topics: Administration, Oral; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin	2008
Increased aldosterone levels in a model of type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2009, Volume: 117, Issue:1 Topics: Actins; Albuminuria; Aldosterone; Animals; Blood Pressure; Cytochrome P-450 CYP11B2; Diabetes Mellit	2009
Growth arrest specific protein 6 participates in DOCA-induced target-organ damage. Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:2 Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Analysis of Variance; Animals; Blood Pressure; Cardio	2009
Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:3 Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Female; Fibrosis; Gene Expression	2009
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. Journal of human hypertension, 2010, Volume: 24, Issue:6 Topics: Aged; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A	2010
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:3 Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis;	2011
Multimarker approach for the prediction of heart failure incidence in the community. Circulation, 2010, Oct-26, Volume: 122, Issue:17 Topics: Aged; Albuminuria; Aldosterone; Biomarkers; C-Reactive Protein; Creatinine; Female; Follow-Up Studie	2010
A multi-marker approach to predict incident CKD and microalbuminuria. Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:12 Topics: Aged; Albuminuria; Aldosterone; Biomarkers; C-Reactive Protein; Causality; Cohort Studies; Comorbidi	2010
Relative contributions of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice. Kidney international, 2011, Volume: 80, Issue:1 Topics: Acetophenones; Albuminuria; Aldosterone; Animals; Blood Pressure; Cell Line; Desoxycorticosterone; D	2011
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:4 Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male;	2011
Have main types of primary aldosteronism different phenotype? Physiological research, 2012, Volume: 61, Issue:4 Topics: Adenoma; Adult; Albuminuria; Aldosterone; Female; Humans; Hyperaldosteronism; Male; Middle Aged; Phe	2012
Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:5 Topics: Adult; Albuminuria; Aldosterone; Blotting, Western; Creatinine; Cross-Sectional Studies; Epithelial	2012
Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity. Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:5 Topics: Adrenergic alpha-1 Receptor Agonists; Albuminuria; Aldosterone; Animals; Blood Pressure; Dose-Respon	2012
High plasma aldosterone is associated with a risk of reversible decreased eGFR in childhood idiopathic nephrotic syndrome. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:4 Topics: Adolescent; Albuminuria; Aldosterone; Blood Volume; Child; Child, Preschool; Echocardiography; Femal	2013
[ALDOSTERONE AND SPIROLACTONES IN THE CLINICAL TREATMENT OF INTERNAL DISEASES (REVIEW OF THE LITERATURE AND ANALYSIS OF PERSONAL CASES)]. Sovetskaia meditsina, 1963, Volume: 27 Topics: Albuminuria; Aldosterone; Blood; Cardiovascular Diseases; Drug Therapy; Humans; Hyperaldosteronism;	1963
[The kidney and diabetes]. La Revue de medecine interne, 2004, Volume: 25 Suppl 4 Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetic Nephropa	2004
Role of aldosterone in diabetic nephropathy. Nephrology (Carlton, Vic.), 2005, Volume: 10 Suppl Topics: Albuminuria; Aldosterone; Animals; Cells, Cultured; Chemokine CCL2; Collagen; Connective Tissue Grow	2005
Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes, 2005, Volume: 54, Issue:10 Topics: Adult; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes	2005
High prevalence of microalbuminuria in chronic heart failure patients. Journal of cardiac failure, 2005, Volume: 11, Issue:8 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Angiotensin-Converti	2005
Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney international, 2006, Volume: 69, Issue:6 Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Collagen; Fibronectins; Gene Expr	2006
Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney international, 2006, Volume: 69, Issue:11 Topics: Albuminuria; Aldosterone; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Sodium	2006
Aldosterone, dietary salt, and renal disease. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:2 Topics: Albuminuria; Aldosterone; Animals; Cross-Sectional Studies; Humans; Hyperaldosteronism; Hypertension	2006
Reduction of salt sensitivity in stroke-prone spontaneously hypertensive rats administered an AT1 receptor antagonist during suckling. American journal of hypertension, 2006, Volume: 19, Issue:9 Topics: Albuminuria; Aldosterone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; An	2006
Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: a reply. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:6 Topics: Albuminuria; Aldosterone; Blood Pressure; Humans; Hypertrophy, Left Ventricular; Sodium Chloride	2007
[Association of aldosterone synthase gene -344 T/C polymorphism with early renal damage in Han nationality with essential hypertension]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2007, Volume: 24, Issue:2 Topics: Adult; Albumins; Albuminuria; Aldosterone; Asian People; China; Cytochrome P-450 CYP11B2; Female; Ge	2007
Protein restriction in lactation confers nephroprotective effects in the male rat and is associated with increased antioxidant expression. American journal of physiology. Regulatory, integrative and comparative physiology, 2007, Volume: 293, Issue:3 Topics: Acetylglucosaminidase; Albuminuria; Aldosterone; Animals; Antioxidants; Biomarkers; Birth Weight; Bo	2007
Sympathoadrenergic and metabolic factors are involved in ambulatory blood pressure rise in childhood obesity. Journal of human hypertension, 2008, Volume: 22, Issue:2 Topics: Adolescent; Albuminuria; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Ma	2008
Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Experimental physiology, 2008, Volume: 93, Issue:7 Topics: Adrenalectomy; Albuminuria; Aldosterone; Animals; Blood Glucose; Collagen Type IV; Cytochrome P-450	2008
Central obesity and hypertension: pathophysiologic role of renal haemodynamics and function. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1995, Volume: 19, Issue:6 Topics: Adult; Albuminuria; Aldosterone; Body Constitution; Body Mass Index; Cardiac Output; Female; Glomeru	1995
Renin-aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration. Diabetes research and clinical practice, 1995, Volume: 27, Issue:3 Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure;	1995
Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition. The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:10 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Albuminuria; Aldosterone; Angiotensin-Converti	1995
Night blood pressure: relation to organ lesions in microalbuminuric type 1 diabetic patients. Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:1 Topics: Adult; Albuminuria; Aldosterone; Arginine Vasopressin; Blood Pressure; Body Mass Index; Circadian Rh	1995
The renal functional reserve in recently diagnosed essential hypertension. Clinical nephrology, 1994, Volume: 41, Issue:4 Topics: Adult; Albuminuria; Aldosterone; Amino Acids; Catecholamines; Creatinine; Humans; Hypertension; Kidn	1994
Nature of elevated blood pressure in normoalbuminuric type I diabetic patients. Essential hypertension? American journal of hypertension, 1993, Volume: 6, Issue:10 Topics: Adolescent; Adult; Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type	1993
Increased red cell sodium lithium countertransport activity, total exchangeable sodium, and hormonal control of sodium balance in normoalbuminuric type 1 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 1993, Volume: 10, Issue:9 Topics: Adolescent; Adult; Aged; Albuminuria; Aldosterone; Antiporters; Blood Pressure; Body Mass Index; Cho	1993
Nocturnal blood pressure elevation is related to adrenomedullary hyperactivity, but not to hyperinsulinemia, in nonobese normoalbuminuric type 1 diabetes. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:2 Topics: Adolescent; Adrenal Medulla; Adult; Albuminuria; Aldosterone; Body Mass Index; Circadian Rhythm; Dia	1996
Albuminuria in untreated patients with primary aldosteronism or essential hypertension. Journal of hypertension, 1995, Volume: 13, Issue:12 Pt 2 Topics: Albuminuria; Aldosterone; beta 2-Microglobulin; Female; Humans; Hyperaldosteronism; Hypertension; Ma	1995
Renal functional reserve in IDDM patients. Diabetologia, 1998, Volume: 41, Issue:1 Topics: Adult; Albuminuria; Aldosterone; Amino Acids; Blood Glucose; Blood Pressure; C-Peptide; Creatinine;	1998
Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension. Journal of hypertension, 1998, Volume: 16, Issue:12 Pt 2 Topics: Adult; Aged; Albuminuria; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Blood Pressure Mon	1998
Resistance to remnant nephropathy in the Wistar-Furth rat. Journal of the American Society of Nephrology : JASN, 1999, Volume: 10, Issue:4 Topics: Albuminuria; Aldosterone; Analysis of Variance; Animals; Blood Pressure Determination; Disease Model	1999
The renin-angiotensin-aldosterone system is suppressed in adults with Type 1 diabetes. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000, Volume: 1, Issue:4 Topics: Adult; Albuminuria; Aldosterone; Angiotensin II; Diabetes Mellitus, Type 1; Female; Glycated Hemoglo	2000
[Bartter's disease associated with hypercorticism, phosphate and magnesium deficiencies and familial renal tubular disease]. Archives francaises de pediatrie, 1975, Volume: 32, Issue:4 Topics: Adrenocortical Hyperfunction; Albuminuria; Aldosterone; Bartter Syndrome; Child; Humans; Hyperaldost	1975
Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. Scandinavian journal of clinical and laboratory investigation, 1992, Volume: 52, Issue:3 Topics: Adult; Aged; Albuminuria; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; beta 2-Microglobul	1992
Exercise-induced proteinuria is attenuated by indomethacin. Medicine and science in sports and exercise, 1992, Volume: 24, Issue:10 Topics: Adult; Albuminuria; Aldosterone; Captopril; Exercise; Hemodynamics; Humans; Indomethacin; Male; Pros	1992
General metabolic response to trauma including pain influence. Acta anaesthesiologica Scandinavica. Supplementum, 1974, Volume: 55 Topics: 17-Hydroxycorticosteroids; Acetylcholine; Adrenocorticotropic Hormone; Albuminuria; Aldosterone; Gro	1974

aldosterone and Albuminuria